Project Grant 2112191
Award Date 6/1/21
Completion Date 5/31/22
Dollars Obligated $256K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Renton, WA 98059, USA
Similar Awards
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $275,000 to Altay Therapeutics, Inc., a biotechnology company, to develop novel small molecule therapies that target disease-causing transcription factors for treating chronic illnesses and cancers. The key goals of this SBIR Phase I project are to: (1) determine the toxicity profile of new inhibitors across human cells, (2) measure drug specificity to the target...
- This National Science Foundation (NSF) SBIR Phase I Project Grant awarded to Eascra Biotech, Inc. is focused on developing and advancing regulatory pathways for space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The $274,990 award, granted on December 15, 2024, aims to demonstrate the comparability of space-manufactured JBNPs to earth-made counterparts, with the goal of revolutionizing cancer treatment by providing a versatile and more...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant for $305,000 awarded to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project seeks to create new cancer treatments designed to target and destroy cancer cells for a broad range of different cancers. The project's broader impact includes addressing critical unmet medical needs and...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award provides $304,870 to Toro Bio, Inc. to develop an automated system for on-site manufacturing of tumor-infiltrating lymphocyte (TIL) cell therapies. The project aims to expand access to personalized cancer treatments by enabling decentralized cell therapy production, which could improve patient outcomes and reduce treatment costs. Key technical goals include manufacturing alpha...
- The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...
- Tartan LLC, operating through its division U1 Bio, Inc., received a $255,730 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation (NSF) Division of Industrial Innovation. The grant supports research titled "Harnessing the Power of Introns for Safe and Effective Therapeutics and Genomic Screening" from July 1, 2021 through December 31, 2021. The STTR Phase I Project Grant aims to support early-stage research and development of technologies...
- This STTR Phase I Project Grant, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is funding the development of a novel tissue-engineered platform for cancer modeling and drug screening. The $275,000 award to Vivosphere LLC will be used to create a more physiologically relevant and versatile high-throughput screening model that can improve the translation rate between preclinical and clinical testing of anti-cancer...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
- This federal Project Grant award, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development and validation of an innovative assay for measuring and targeting the drug target sphingosine kinase (SphK) in cancer cells. Piccolo Biosystems, Inc., an early-stage biotechnology company, will collaborate with scientists at the University of Washington to leverage their patent-pending...
- This $304,733 STTR Phase I Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program is funding the development of a novel optical metabolic flow cytometer to rapidly screen T cell fitness for Chimeric Antigen Receptor (CAR) T-cell therapy. The awardee, Selight, LLC, aims to create a high-throughput screening system to identify patients at high risk of CAR T-cell manufacturing failure, which can occur in up to 69% of...